iPSC-derived MSCs CYP-001 clinical trials
Also written CYP-001.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses iPSC-derived MSCs CYP-001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CYP-001
- 2
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Cynata Therapeutics Limited (3)
Studies
Open first, then newest update. How each study uses iPSC-derived MSCs CYP-001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHDTerminatedPhase 2Cynata Therapeutics LimitedNCT05643638Written as CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)How we know
- The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying CauseCompletedPhase 1Cynata Therapeutics LimitedNCT04537351Written as CYP-001How we know
- A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host DiseaseCompletedPhase 1Cynata Therapeutics LimitedNCT02923375Written as Mesenchymoangioblast-derived mesenchymal stem cellsHow we know